These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs. Somani AK; Ibrahim SF; Tassavor M; Yoo J; Farberg AS J Clin Aesthet Dermatol; 2024 Jan; 17(1):41-44. PubMed ID: 38298751 [TBL] [Abstract][Full Text] [Related]
31. Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry. Azimi A; Lo K; Kim J; Fernandez-Penas P J Dermatol Sci; 2020 Aug; 99(2):119-127. PubMed ID: 32651104 [TBL] [Abstract][Full Text] [Related]
32. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. Que SKT; Zwald FO; Schmults CD J Am Acad Dermatol; 2018 Feb; 78(2):237-247. PubMed ID: 29332704 [TBL] [Abstract][Full Text] [Related]
33. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. Hyams DM; Covington KR; Johnson CE; Plasseraud KM; Cook RW Future Oncol; 2021 Feb; 17(5):517-527. PubMed ID: 33021104 [No Abstract] [Full Text] [Related]
34. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384 [TBL] [Abstract][Full Text] [Related]